Policy Briefings

Section 232 Pharma Tariffs Expand Today: What Manufacturers Need to Know

MFN Deal Includes Revenue-Sharing With HHS on Overseas Sales

China Aims for 25% of Global First-in-Class Drugs by 2030

White House Secures $19.6B in Pharma Manufacturing Pledges

Trump Gives Generic Drugmakers Two Years to Reshore Before Tariffs Hit

Warren, Scott revive bill to map foreign control of US drug supply

Congress Proposes Federal Oversight for US-China Drug Licensing Deals

FDA Shakeup Continues: Høeg Fired, Davis Named Acting CDER Head

Trump Confirms Makary Exit; Diamantas Named Acting Chief

Regeneron Closes MFN Deal; Offers Gene Therapy Free

US Pharma Tariffs: 100% Headline Rate, Far Lower Real-World Impact

The European Biotech Act, Explained

Multistate Lawsuit Targets CDC Childhood Vaccine Rollback

Trump’s Tariffs Are Off — Or Are They? What Pharma Does Next

FDA and EMA Issue Joint AI Principles for Drug Development

EU Critical Medicines Act: What Manufacturing Leaders Must Prepare For

TrumpRx Launches: Will Direct-to-Consumer Platform Actually Lower Drug Costs?

J&J Strikes Drug Pricing Deal with Trump Administration

Nine Drugmakers Sign Trump MFN Deals in Single Day, Pledge $150B in US Manufacturing

US–UK Deal Sets Zero Tariffs, Raises UK Drug Value Thresholds

Trump Administration Launches Review of Global Drug Pricing Practises

TAPI Appoints Serge Rogasik as Chief Executive Officer

ALK Expands Catalent Partnership to Secure Long-Term Allergy Tablet Supply

OnDosis and Adare Pharma Solutions Launch U.S. ADHD Drug-Device Collaboration

Ensera Launches Alliance Network for Drug-Device Combination Products

Merck Opens €70M Expansion at St. Louis ADC Manufacturing Center

NorthStar Medical Technologies Secures Up to $185M Growth Capital Facility

Piramal Pharma Solutions Receives $1.75M Ontario Investment for Aurora Site

Minaris Adds Viral Vectors Business Unit to Expand CGT Model

Genezen Partners on AAV9 Gene Therapy for Ultra-Rare ARCA2 Disorder

ESTEVE CDMO Expands Morton Grove Facility With $33M Total Investment

Forge Biologics Partners With TECPR2 Research Foundation on AAV Gene Therapy

Axplora Completes First R&D Batches of Exatecan for ADC Developers

Serán Bioscience Announces Growth Investment to Expand Commercial Manufacturing

Quotient Sciences and Acesion Pharma Launch AI Formulation Collaboration

CARBOGEN AMCIS Completes First FDA Pre-Approval Inspection at Vionnaz

Biodextris Appoints Clement Fourny as Chief Executive Officer

Lifecore Biomedical Agrees to $663.7M Acquisition by Webster Equity Partners

4basebio Partners With TriLink on Cell Therapy Manufacturing Program

European CDMO Landscape 2025: Download the latest edition